DSIP
Research OnlyA nonapeptide discovered in 1977 that was initially thought to induce delta wave sleep. Research has shown broader neuromodulatory effects including stress-protection and analgesia, though its role as an endogenous sleep factor remains controversial.
Delta Sleep Inducing Peptide · Delta Sleep-Inducing Peptide · WAGGDASGE
7 human studies
- Preclinical
- 65%
- Clinical
- 35%
Based on 20 cited sources
clinically demonstrated · low confidence
Demonstrated effect magnitude — not a recommendation or safety claim.
Research Depth 57 (1A 24: multiple small double-blind placebo-controlled human insomnia trials, all from one Swiss group [Schneider-Helmert/ Schoenenberger 6689058, 3622582, 3792404, 7028502], each n<50, controlled- clinical-trial grade not independent parallel RCTs; 1B 10: double-blind but small/single-group/high inter-individual variability, "some concerns"; 1C 5: total human N ~50-100; 1D 11: direct population/outcome for insomnia, IV route; 1E 7: substantial preclinical program across antioxidant/hypoxia/ cold-stress/antinociception/neuroendocrine models). Mechanism 43 (2A 10: no validated DSIP receptor, target inferred, endogeneity itself disputed, serotonergic/opioid roles shown only via antagonist blockade of downstream systems [methysergide 6132892, naloxone 2853064]; 2B 12: proximal signaling partially known; 2C 12: dose-dependent antinociception + parabolic dose- response across models in vivo; 2D 9: confirmed in mammalian in vivo). Plausibility 62 (3A 22: mechanism->sleep-surrogate established with human outcome data but >=1 unproven receptor link; 3B 20: coherent with serotonergic sleep biology; 3C 12: mixed-to-supportive class analogy from serotonergic/sleep neuropeptides; 3D 8: moderately broad multi-system claim set [sleep+stress+analgesia+neuroendocrine]). Global Coverage 48 (4A 18: human sleep work single Swiss group, preclinical replicated by independent Russian/Japanese/Israeli groups; 4B 16: 4+ countries; 4C 14: ~few dozen studies, diverse contexts but research largely abandoned post-1990s; 4D 0: no regulatory approval anywhere). Community Experience 47 (5A 14: niche but persistent sleep-optimization use; 5B 16: multi-year track record; 5C 8: reports inconsistent across users with tolerance + vivid dreams noted; 5D 9: no serious adverse signal, isolated minor reports). Effectiveness basis clinical (low confidence): placebo-controlled double-blind trials show sleep normalization rather than sedation on functional sleep endpoints, but effect is modest, highly variable, surrogate/functional, single-group, old, with no head-to-head and no large modern trials.
The proposed mechanisms of DSIP are based on a mix of human studies from the 1980s and animal research. The peptide’s exact receptor target remains unidentified, and whether it truly exists as an endogenous compound is still debated.
How It Works (Simplified)
DSIP appears to act as a neuromodulator through several interconnected pathways:
Modulates serotonergic neurotransmission to promote natural sleep patterns rather than acting as a sedative. Effects most pronounced in sleep-disturbed individuals.
Activates antioxidant enzymes (SOD, catalase) and stabilizes cell membranes, reducing oxidative damage under various stress conditions.
In animal studies, centrally administered DSIP produced antinociception that was reversed by naloxone, indicating involvement of the endogenous opioid system. No human pain data exist.
Influences cortisol, growth hormone, and other hormones that affect sleep-wake cycles and stress responses.
Key Research: Yehuda & Mostofsky (1982) found that DSIP-induced sleep signs were blocked by the serotonin antagonist methysergide, implicating serotonergic mediation. PMID:6132892
Important Limitations
- No specific DSIP receptor has been identified
- Whether DSIP exists endogenously remains controversial (Kovalzon 2006)
- Most studies are from 1980s-1990s with outdated methodology
- High inter-individual variability in response rates
- Blood-brain barrier penetration mechanism unclear
- Research largely abandoned after 1990s in favor of newer sleep medications
Reported positives
- Improved sleep onset and quality reported
- Reduced stress and anxiety noted
- Natural-feeling sleep enhancement cited
- Well-tolerated with minimal morning grogginess
Reported negatives
- Effects inconsistent across users
- Tolerance develops with regular use
- Limited suppliers and quality control concerns
- Some users report vivid or disturbing dreams
“Niche following in sleep optimization community. Often discussed alongside melatonin and sleep peptides.”
Self-reported, unverified accounts — not clinical evidence and no substitute for the cited research. Anecdotes are prone to selection bias and placebo effects.
| NCT ID | Title | Peptide | Phase | Status | Completion |
|---|---|---|---|---|---|
| Historical | Swiss clinical studies in insomnia (1980s) | DSIP | Phase Early clinical | Completed | - |
| Historical | Russian clinical investigations (1980s-1990s) | DSIP | Phase Clinical research | Completed | - |
Russian clinical investigations (1980s-1990s)
Based on early human studies: Initial effects on sleep architecture may begin. Some users report improved sleep quality within days. High variability in response noted across studies.
PMID:7028502Human studies showed continued improvement in sleep-disturbed individuals. The 'normalizing' rather than sedating effect becomes more apparent. Stress-protective benefits may emerge based on preclinical data.
PMID:6391925Swiss follow-up studies reported that sleep normalization was maintained through a one-week follow-up period in some patients. Response variability remains high.
PMID:3792404Long-term human data is limited; published trials extended only to short follow-up periods of about one week. Optimal treatment duration is unknown, and no controlled long-term studies are available.
Research-based observations
This timeline reflects observations from published clinical and preclinical studies. Individual responses may vary significantly. This is not a guarantee of effects or a dosing schedule. Consult qualified healthcare providers for personalized guidance.
Good Signs (6 indicators)
Warning Signs (5 indicators)
Bad Signs (6 indicators)
For Research Evaluation Only
These quality indicators are general guidelines based on typical peptide characteristics. Professional laboratory testing (HPLC, mass spectrometry) provides definitive quality verification. This checklist is for initial visual evaluation only.
Selank
CompatibleBoth are neuropeptides with anxiolytic and stress-protective properties. Selank is better characterized with more consistent research. No interaction studies available.
Semax
CompatibleNon-overlapping primary mechanisms. DSIP focuses on sleep/stress while Semax is primarily nootropic. Theoretical complementary benefits for cognitive recovery.
Epithalon
CompatibleEpithalon targets telomerase and circadian regulation while DSIP affects sleep architecture. Both may influence circadian rhythms through different pathways.
Melatonin
CautionBoth affect sleep-wake cycles. Combining sleep-modulating compounds may have unpredictable effects. Monitor for excessive sedation if used together.
Research Note: Interaction data is based on published literature, mechanistic understanding, and theoretical considerations. Most peptide combinations lack direct clinical study. This information is for educational purposes only and does not constitute medical advice. Always consult qualified healthcare providers.
Key Studies Cited
Full reference list available on request. All citations link to PubMed for verification.
This dossier synthesizes available evidence from peer-reviewed literature, regulatory documents, and clinical trial registries. Evidence strength ratings follow a modified GRADE approach.
For complete methodology details, see our Methodology page.
Important Disclaimer
This dossier is for educational purposes only and does not constitute medical advice. Always consult a qualified healthcare provider before making health decisions.
Get Research Alerts
New dossiers and major study summaries delivered to your inbox. Evidence-graded, citation-backed research you can trust.
No spam. Unsubscribe anytime.
Compare DSIP
Related Peptides
Alixorexton
ALKS 2680 · ALKS-2680
An oral orexin receptor 2 (OX2R) agonist developed by Alkermes for narcolepsy type 1 (NT1). Phase 2 clinical trials demonstrated improvements in excessive daytime sleepiness and cataplexy with once-daily dosing. Represents a novel approach to restore orexin signaling in patients who have lost orexin-producing neurons.
Cerebrolysin
FPF-1070 · N-PEP-12 · Renacenz
Cerebrolysin is a porcine brain-derived peptide mixture approved in 50+ countries for stroke, dementia, and traumatic brain injury. It is NOT FDA-approved in the United States despite decades of international clinical use. Contains neurotrophic peptide fragments mimicking BDNF, GDNF, NGF, and CNTF. Mixed Phase 3 results but positive meta-analyses and widespread adoption in Europe, Asia, and Latin America.
Cerluten
Brain cytamin · Cerebral peptides · A-5 brain peptides
A cytamin-class peptide supplement derived from brain tissue, part of the Russian bioregulator framework. Marketed as an oral supplement for cognitive support and neuroprotection. Contains peptide complexes rather than defined sequences. No Western clinical validation.
Cortexin
Cortexinum · Polypeptide brain extract · Bovine brain cortex polypeptides
A Russian neuropeptide complex derived from porcine or bovine cerebral cortex, approved in Russia and CIS countries for neurological conditions. Contains low molecular weight polypeptides (1,000-10,000 Da) with proposed neurotrophic and neuroprotective properties. NOT approved by FDA, EMA, or other Western regulatory agencies. Evidence comes primarily from Russian studies with limited Western validation.
Dihexa
PNB-0408 · N-hexanoic-Tyr-Ile-(6) aminohexanoic amide
An angiotensin IV analog developed by Washington State University researchers, claimed to enhance cognition through HGF/c-Met signaling. Gained attention for extreme potency claims (10 million times more potent than BDNF), but evidence is limited to rodent studies from a single research group with no human clinical trials. Sold as a research chemical with unknown safety profile.
N-Acetyl Selank Amidate
NA-Selank · N-Acetyl Selank · Acetyl-Selank-Amidate +1
A modified version of Selank with N-terminal acetylation and C-terminal amidation designed to enhance stability and bioavailability. While the parent compound Selank is approved in Russia, N-Acetyl Selank Amidate has no independent clinical research and relies entirely on extrapolated claims from Selank studies.